IGC
IGC Pharma, Inc.
1W: -1.1%
1M: +7.6%
3M: -14.8%
YTD: -3.8%
1Y: -10.1%
3Y: -17.6%
5Y: -85.3%
$0.29
+0.01 (+5.22%)
After Hours: $0.27 (-0.01, -4.07%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$27.2M
52W Range0.24-0.5
Volume764,094
Avg Volume414,661
Beta0.30
Dividend—
Analyst Ratings
Company Info
CEORam Mukunda
Employees67
SectorHealthcare
IndustryBiotechnology
IPO Date2006-05-24
Websiteigcpharma.com
10224 Falls Road
Potomac, MD 20854
US
Potomac, MD 20854
US
301 983 0998
About IGC Pharma, Inc.
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
Latest News
electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
IGC Pharma reports results
IGC Pharma, Inc. (NYSEAMERICAN:IGC) Short Interest Up 15.9% in February
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
IGC Pharma (NYSEAMERICAN:IGC) Stock Price Down 1.2% – Time to Sell?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Mukunda Ram | M-Exempt | 50,000 | — | 2026-02-03 |
| Mukunda Ram | A-Award | 16,667 | — | 2026-02-03 |
| Mukunda Ram | A-Award | 66,666 | — | 2026-02-03 |
| PRINS RICHARD K | M-Exempt | 100,000 | — | 2026-01-19 |
| PRINS RICHARD K | M-Exempt | 100,000 | — | 2026-01-19 |